At its Annual General Meeting in early April 2026, Danang Pharmaceutical – Medical Equipment JSC (Ticker: DDN) approved a new development roadmap, marking a transition from scale expansion to optimizing growth quality.
The key strategic directions include:
-
Breakthrough Financial Targets: Following a comprehensive restructuring phase, the company expects 2026 revenue to reach 950 billion VND, a 2.3-fold increase over 2025. For the first quarter of 2026 alone, pre-tax profit is projected to surge by 224% compared to the same period last year.
-
Portfolio Streamlining: Dapharco has conducted a rigorous project review, deciding to terminate underperforming ventures to concentrate on core strengths. Specifically, the company will shut down its NeoVita facility in Ho Chi Minh City to focus on its Danang location and has postponed the construction of an ISO-standard cosmetics factory until 2027 to ensure financial prudence.
-
Expanding Hospital Channel (ETC) Market Share: The enterprise plans to increase its presence in the Southern and Central regions while boosting import entrustment services and international partnerships to bring high-quality pharmaceuticals and medical supplies to Vietnam.
-
Employee Incentives through Stock Options: Shareholders approved an Employee Stock Ownership Plan (ESOP) scheduled for 2029. The prerequisite for this issuance is maintaining a minimum compound annual profit growth rate of 20% during the evaluation period.
In the long term, the company aims to develop its own branded product portfolio to enhance profit margins and optimize the utilization of its current asset and real estate holdings. To ensure sufficient working capital for these ambitious plans, the company will not distribute dividends for the 2025 fiscal year.
Source: https://vietnamfinance.vn/duoc-da-nang-dat-muc-tieu-tang-truong-vuot-bac-trong-nam-2026-d142782.html